Floatz logo

Enmd-2076

Advanced Fibrolamellar Carcinoma

CASI pharmaceuticals, Inc.Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

26 Active assets in the Advanced Fibrolamellar Carcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Children's Oncology Group
Phase 3BB
FLUOROURACILUM
M.D. Anderson Cancer Center
Phase 3BB
Nivolumab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2B
Sorafenib
St. Jude Children's Research Hospital
Phase 3B
Inno-206
Children's Oncology Group
Phase 3B

View all 37 →

Same molecule, other indications

Enmd-2076 is also rated in:

adult hepatocellular carcinomaDormant
B
Indicative ·
57 / 100
View asset →
Ovarian Clear Cell CarcinomaDormant
B
Indicative ·
57 / 100
View asset →
fallopian tube cancerDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →